@article{3032351,
    title = "Female Patient with Two Simultaneous Giants Facial Basal Cell Carcinomas
Demonstrates a Positive Response to Vismodegib as a Monotherapy",
    author = "Theotokoglou, Sofia and Sgouros, Dimitrios and Theodoropoulos, and Konstantinos and Syrmali, Anna and Polyderas, George and Katoulis, and Alexander C.",
    journal = "Indian Journal of Dermatology",
    year = "2021",
    volume = "66",
    number = "6",
    publisher = "Wolters Kluwer--Medknow Publications",
    issn = "0019-5154",
    doi = "10.4103/ijd.ijd_37_21",
    keywords = "Basal cell carcinoma; giant basal cell carcinoma; monotherapy;
vismodegib",
    abstract = "Basal cell carcinoma (BCC) is the most frequent histological type of
cancer in the world and accounts for approximately 80% of all skin
cancers. In the majority of cases, they are slow-growing, low metastatic
potential tumors, easy to cure by surgical or nonsurgical procedures.
Giant BCC (GBCC) is a rare variant of BCC and according to the American
Joint Committee on Cancer, this includes lesions with a diameter larger
than 5 cm. GBCC’s incidence has been reported to be less than 1%, and
it displays a more aggressive behavior with both local invasion and
higher metastatic potential. Archodaki et al. specifically reported that
metastasis was present in 17.6% of GBCC patients during the primary
examination. Patients with GBCC who are not suitable for either surgery
or radiotherapy since 2012 seem to have another therapeutic option.
Vismodegib is an oral small-molecule inhibitor of the Hedgehog pathway
(HPI) that was approved for treating metastatic or locally advanced BCC
in patients who are poor candidates for surgery or radiotherapy. In this
case, we present a woman with two simultaneous facial GBCCs who was
treated successfully using vismodegib as a monotherapy."
}